Teva Pharmaceuticals Archives

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-’749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)

Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscience Data show TEV-’749 drug delivery technology resulted in no occurrence of Post-Injection Delirium/Sedation Syndrome (PDSS) events to date Real-world analyses of UZEDY (risperidone) subcutaneous long-acting injectable reveal high adherence rates and utilization in adults [...]

Teva Statement on European Commission Decision; Company to Appeal

Teva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes are extreme, untested, and factually unsupported The company intends to appeal the outcome and is fully prepared to mount its defense Teva has supported the MS community since 1996 and will not be distracted from providing access [...]